News Release

Reactive arthritis is fueled by amyloid protein during salmonella infection

New research by Temple scientists published by PLOS Pathogens

Peer-Reviewed Publication

Temple University Health System

(Philadelphia, PA) - Like the infrastructure of an apartment building, a fibrous protein known as curli amyloid that is produced by bacteria provides the supportive framework for biofilms - thick extracellular substances made by bacteria that enable multiple bacterial cells to assemble, survive, and thrive together. Curli amyloid, however, is also a key factor in diarrheal illness brought about by bacterial infection, and its harmful effects may extend well beyond the gastrointestinal tract.

In particular, infections with Salmonella bacteria, which produce curli amyloid, are implicated in an insidious, painful inflammatory condition known as reactive arthritis (ReA), which affects about five percent of people who have been infected with bacteria that cause gastrointestinal illness. There are no treatments for ReA, and very little is known about how or why it develops.

Now in new work, researchers at the Lewis Katz School of Medicine at Temple University (LKSOM) show that in mice infected with Salmonella enterica Typhimurium - a common cause of food-borne diarrheal illness - curli provokes the generation of autoantibodies and joint inflammation. The most damaging of these effects were linked to systemic exposure to curli, revealing a hidden harm inflicted by bacterial components that escape the intestinal tract.

The study was published online July 9th in the journal PLOS Pathogens.

"We found specifically that if curli stays in the intestines, its negative inflammatory effects are limited," explained Cagla Tukel, PhD, Associate Professor in the Department of Microbiology and Immunology at LKSOM and senior author on the new study. "But in susceptible individuals, if curli escapes the intestinal tract and enters the circulation, an autoimmune reaction ensues."

The research was carried out in collaboration with Dr. Aaron P. White and other scientists at the Vaccine and Infectious Disease Organization-International Vaccine Centre, University of Saskatchewan, Canada.

Dr. Tukel and Dr. White's laboratories developed a mouse model in which animals were orally infected with wild-type S. Typhimurium, meant to mimic food- or water-borne transmission in humans. The infectious inoculum consisted of S. Typhimurium cells capable of producing curli, though no curli was present in the inoculum itself, enabling the researchers to examine curli production and its impact on autoimmunity in vivo. For comparison, some mice were infected with a mutated strain of S. Typhimurium incapable of curli production.

Within a week of infection with wild-type S. Typhimurium, bacterial clusters were evident in the cecum and colon of mice, and the bacteria were producing curli. Oral infection further led to the generation of autoantibodies against curli/DNA complexes, which are critical to biofilm formation. Autoantibody production was attributed to the systemic reach of curli.

Evaluation of knee joints and serum from mice with wild-type S. Typhimurium confirmed the systemic presence of curli-induced autoantibodies and joint inflammation. Moreover, chronic synovial inflammation, affecting the fluid surrounding joints, and bone resorption (bone break down), which are hallmarks of ReA, were observed.

"Our findings indicate that curli is a major component of Salmonella that drives autoimmune reactions," Dr. Tukel said. "In mice, these reactions were triggered within six weeks of infection, demonstrating that the expression of a bacterial component in the intestine can lead to subsequent autoimmune responses."

A protein known as HLAB27, the production of which is associated with a specific genetic variation, is a risk factor for the development of ReA. "The presence of pathogenic curli in the microbiota may precipitate or exacerbate autoimmunity in individuals with HLAB27," Dr. Tukel noted.

Dr. Tukel and her team plan next to determine whether the new findings translate to humans, and whether curli proteins from other pathogenic bacteria, like E. coli, are capable of generating similar autoimmune reactions. Her group is also investigating whether curli plays a role in exaggerating other autoimmune diseases, such as systemic lupus erythamatosus (SLE), where genetic risk factors are involved.

An additional area of study for Dr. Tukel's team concerns a suspected relationship between disease-causing bacterial curli and amyloid disorders, such as Parkinson's and Alzheimer's disease. "Recent research in Parkinson's disease mouse models suggests that curli amyloid fuels neurodegeneration," Dr. Tukel said. "The ability of enteric bacterial curli to escape the intestine and reach the systemic circulation raises questions about a potential role in neurodegenerative processes."


Other researchers who contributed to the new work include Amanda L. Miller, Nicole J. Medeiros, Lauren K. Nicastro, Sarah A. Tursi, Yi Zhang, and R. Paul Wilson, Department of Microbiology and Immunology, LKSOM; J. Alex Pasternak and Heather L. Wilson, Vaccine and Infectious Disease Organization-International Vaccine Centre, Saskatoon, Saskatchewan, Canada; Elizabeth G. Hansen, Ryan Krochak, Akosiererem S. Sokaribo, Keith D. MacKenzie, Melissa B. Palmer, Dakoda J. Herman, Nikole L. Watson, and Aaron P. White, Vaccine and Infectious Disease Organization-International Vaccine Centre and Department of Biochemistry, Microbiology and Immunology, University of Saskatchewan.

The research was supported in part by funding from the U.S. Public Health Service, a division of the U.S. Department of Health and Human Services.

About Temple Health

Temple University Health System (TUHS) is a $2.2 billion academic health system dedicated to providing access to quality patient care and supporting excellence in medical education and research. The Health System consists of Temple University Hospital (TUH); TUH-Episcopal Campus; TUH-Jeanes Campus; TUH-Northeastern Campus; The Hospital of Fox Chase Cancer Center and Affiliates, an NCI-designated comprehensive cancer center; Temple Transport Team, a ground and air-ambulance company; Temple Physicians, Inc., a network of community-based specialty and primary-care physician practices; and Temple Faculty Practice Plan, Inc., TUHS's physician practice plan comprised of more than 500 full-time and part-time academic physicians in 20 clinical departments. TUHS is affiliated with the Lewis Katz School of Medicine at Temple University.

Temple Health refers to the health, education and research activities carried out by the affiliates of Temple University Health System (TUHS) and by the Katz School of Medicine. TUHS neither provides nor controls the provision of health care. All health care is provided by its member organizations or independent health care providers affiliated with TUHS member organizations. Each TUHS member organization is owned and operated pursuant to its governing documents.

It is the policy of Temple University Health System that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.